Melissa Kapulu/Wellcome Open Res
Safety and immunogenicity of varied doses of R21/Matrix-M vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang, S.
Datoo, M. S.
Otieno, E.
Muiruri, C.
Bellamy, D.
Gathuri, E.
Ngoto, O.
Musembi, J.
Provstgaard-Morys, S.
Stockdale, L.
Aboagye, J.
Woods, D.
Lawrie, A.
Roberts, R.
Keter, K.
Kimani, D.
Ndungu, F.
Kapulu, M.
Njau, I.
Orindi, B.
Ewer, K. J.
Hill, A. V. S.
Bejon, P.
Hamaluba, M.
Wellcome Open Res, (2023). 8:450
Equity for excellence in academic institutions: a manifesto for change.Wedekind, L.
Noe, A.
Mokaya, J.
Tamandjou, C.
Kapulu, M.
Ruecker, A.
Kestelyn, E.
Zimba, M.
Khatamzas, E.
Eziefula, A. C.
Mackintosh, C. L.
Nascimento, R.
Ariana, P.
Best, D.
Gibbs, E.
Dunachie, S.
Hadley, G.
Ravenswood, H.
Young, B.
Kamau, C.
Marsh, K.
McShane, H.
Hale, R.
McPhilbin, E.
Ovseiko, P. V.
Oxford Equity in Academia, consortium
Surender, R.
Worland, C.
White, L. J.
Matthews, P. C.
Wellcome Open Res, (2021). 6:142
Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia.Kunda-Ng'andu, E. M.
Simuyandi, M.
Kapulu, M.
Chirwa-Chobe, M.
Mwanyungwi-Chinganya, H.
Mwale, S.
Chilengi, R.
Sharma, A.
Wellcome Open Res, (2021). 6:31
